{"id":18532,"date":"2021-10-14T12:22:54","date_gmt":"2021-10-14T12:22:54","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=80532"},"modified":"2021-10-14T12:22:54","modified_gmt":"2021-10-14T12:22:54","slug":"hyris-brings-to-market-worldwide-a-new-test-that-can-quickly-detect-the-bodys-t-cell-immune-response-to-sars-cov-2-thanks-to-a-partnership-with-singapores-duke-nus-medical-2","status":"publish","type":"post","link":"https:\/\/myanmarnewswire.com\/hyris-brings-to-market-worldwide-a-new-test-that-can-quickly-detect-the-bodys-t-cell-immune-response-to-sars-cov-2-thanks-to-a-partnership-with-singapores-duke-nus-medical-2\/","title":{"rendered":"Hyris Brings to Market Worldwide a New Test That Can Quickly Detect the Body\u2019s T-Cell Immune Response to SARS-CoV-2, Thanks to a Partnership With Singapore\u2019s Duke-NUS Medical"},"content":{"rendered":"

Hyris developed a rapid T-cell test to track patients’ immunity levels to SARS-CoV-2 for global clinical use after having inked an exclusive licensing agreement with Duke-NUS Medical School. This new solution leverages the Hyris SystemTM, a proprietary platform that enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.<\/h4>\n
\n
\n
\"\"<\/a><\/p>\n

Hyris supports research over COVID-19 Immunity<\/p>\n<\/div>\n<\/div>\n

\n

LONDON, Oct. 14, 2021 (GLOBE NEWSWIRE) — After almost two years of fight against COVID-19, governments, NGOs, and corporations are now focusing on strategies and solutions to boost population immunity and move onto the next phase – possibly out of the pandemic.<\/p>\n<\/div>\n<\/div>\n

Hyris<\/strong>, a global, innovation-based biotechnology company renowned for its inclusive approach to genetic analysis, offers a wide range of solutions to support medical professionals and decision-makers in the fight against COVID-19. The proprietary genetic testing\u00a0Hyris SystemTM<\/sup><\/strong>\u00a0has been successfully used to detect the presence of the Coronavirus on surfaces and environments (the\u00a0SARS-CoV-2 Environmental<\/strong>\u00a0test) and the infection COVID-19 into individuals (SARS-CoV-2 Human test<\/strong>). The tests have been able to reliably detect\u00a0the presence of all the main Variants of Concern since July 2020<\/a>, helping to keep people safe around the world effectively.<\/p>\n

“Alongside with limiting the spread of SARS-CoV-2 new variants and potential hotspots, getting high immunity rates among populations is the number one priority for policymakers and health institutions,”\u00a0<\/em>says\u00a0Stefano Lo Priore, Founder and CEO at Hyris<\/strong>. “Hyris integrated its solutions with a simple yet effective test, to measure a patient T-cell immune response to the SARS-CoV-2 virus, which causes COVID-19.”<\/em><\/p>\n

The T-cell clinical test kit was developed through\u00a0an exclusive licensing agreement between Hyris and Duke-NUS Medical School<\/strong>. “This new kit enables quick evaluation of T-cell immune responses in COVID-19 convalescent patients as well as vaccinated people,<\/em>” adds\u00a0Isabella Della Noce, Chief Biologist at Hyris<\/strong>. “This is a new dimension for vaccine strategies as we face the threat of new virus variants.”<\/em><\/p>\n

Led by\u00a0Professor Antonio Bertoletti<\/strong>\u00a0from the Programme in Emerging Infectious Diseases at Duke-NUS, the research team discovered a simple and rapid method to measure the T-cell immune response to the SARS-CoV-2 virus. The study, titled “Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals<\/em><\/a>“,\u00a0was published in\u00a0the Journal of Clinical Investigation<\/em><\/a>.<\/em><\/p>\n

According to\u00a0Duke-NUS’ press release<\/a>, this discovery allows a rapid and large-scale expansion of studies to track T-cell activity across the world while not requiring specialised or expensive equipment, helping to define the correlates of protection from T-cells and antibodies for the development of COVID-19 vaccines.<\/p>\n

Many progressive organisations and medical centres worldwide have already chosen the Hyris System\u2122 as the ideal ‘Point of Care’ solution in the fight against COVID-19. Such a test is a prime example of how scientific innovation is\u00a0key<\/strong>\u00a0to the fight against the SARS-CoV-2 virus. “Today, more than ever before, we need\u00a0wider access to diagnostic\u00a0<\/strong>systems and tests, but also to\u00a0support and validate vaccination campaigns around the world,<\/strong><\/em>”\u00a0concludes Lo Priore.<\/p>\n

Contact a Hyris expert to discover how to perform beyond your current diagnostic capability\u00a0<\/em>info@hyris.net<\/u><\/em><\/a>.<\/em><\/p>\n

Related Files<\/b><\/p>\n

JCI_Rapid measurement of SARS-CoV-2 spike T cells.pdf<\/a><\/p>\n

Related Images<\/b><\/strong><\/p>\n

\"\"<\/a><\/p>\n

Image 1: Hyris supports research over COVID-19 Immunity<\/b><\/strong><\/a><\/p>\n

Hyris new Test quickly detects the body’s T-cell immune response to SARS-CoV-2<\/p>\n

This content was issued through the\u00a0press release distribution service at Newswire.com<\/a>.<\/p>\n

Attachment<\/strong><\/p>\n